001     126144
005     20240228140810.0
024 7 _ |a 10.18632/oncotarget.3369
|2 doi
024 7 _ |a pmid:25879388
|2 pmid
024 7 _ |a pmc:PMC4496193
|2 pmc
037 _ _ |a DKFZ-2017-02259
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Bhatia, Shilpa
|b 0
245 _ _ |a Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization.
260 _ _ |a [S.l.]
|c 2015
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508401287_6846
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The expression of members of the Eph family of receptor tyrosine kinases and their ephrin ligands is frequently dysregulated in medulloblastomas. We assessed the expression and functional role of EphB1 in medulloblastoma cell lines and engineered mouse models. mRNA and protein expression profiling showed expression of EphB1 receptor in the human medulloblastoma cell lines DAOY and UW228. EphB1 downregulation reduced cell growth and viability, decreased the expression of important cell cycle regulators, and increased the percentage of cells in G1 phase of the cell cycle. It also modulated the expression of proliferation, and cell survival markers. In addition, EphB1 knockdown in DAOY cells resulted in significant decrease in migration, which correlated with decreased β1-integrin expression and levels of phosphorylated Src. Furthermore, EphB1 knockdown enhanced cellular radiosensitization of medulloblastoma cells in culture and in a genetically engineered mouse medulloblastoma model. Using genetically engineered mouse models, we established that genetic loss of EphB1 resulted in a significant delay in tumor recurrence following irradiation compared to EphB1-expressing control tumors. Taken together, our findings establish that EphB1 plays a key role in medulloblastoma cell growth, viability, migration, and radiation sensitivity, making EphB1 a promising therapeutic target.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antigens, CD29
|2 NLM Chemicals
650 _ 7 |a Cell Cycle Proteins
|2 NLM Chemicals
650 _ 7 |a Neoplasm Proteins
|2 NLM Chemicals
650 _ 7 |a RNA, Small Interfering
|2 NLM Chemicals
650 _ 7 |a Receptor, EphB1
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins pp60(c-src)
|0 EC 2.7.10.2
|2 NLM Chemicals
700 1 _ |a Baig, Nimrah A
|b 1
700 1 _ |a Timofeeva, Olga
|b 2
700 1 _ |a Pasquale, Elena B
|b 3
700 1 _ |a Hirsch, Kellen
|b 4
700 1 _ |a MacDonald, Tobey J
|b 5
700 1 _ |a Dritschilo, Anatoly
|b 6
700 1 _ |a Lee, Yi Chien
|b 7
700 1 _ |a Henkemeyer, Mark
|b 8
700 1 _ |a Rood, Brian
|b 9
700 1 _ |a Jung, Mira
|b 10
700 1 _ |a Wang, Xiao-Jing
|b 11
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 12
|u dkfz
700 1 _ |a Rodriguez, Olga
|b 13
700 1 _ |a Albanese, Chris
|b 14
700 1 _ |a Karam, Sana D
|b 15
773 _ _ |a 10.18632/oncotarget.3369
|g Vol. 6, no. 11, p. 8929 - 8946
|0 PERI:(DE-600)2560162-3
|n 11
|p 8929 - 8946
|t OncoTarget
|v 6
|y 2015
|x 1949-2553
909 C O |o oai:inrepo02.dkfz.de:126144
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOTARGET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOTARGET : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21